MS and Demyelinating Disorders

Catch up on any of the neurology news headlines you may have missed over the course of March 2025, compiled all into one place by the NeurologyLive® team.

The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania discussed evolving insights into the cellular immunology of multiple sclerosis. [WATCH TIME: 4 minutes]

The ENABLE phase 4 study will evaluate the real-world safety, efficacy, and patient experience of ublituximab in relapsing multiple sclerosis over a 96-week period.

Here's some of what is coming soon to NeurologyLive® this week.

Long-term data from a phase 2 study extension suggest that frexalimab, a CD40L inhibitor, maintains disease control and is well-tolerated in relapsing multiple sclerosis, reinforcing its potential as a next-generation treatment.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 4, 2025.

The company's phase 3 MUSETTE trial reported that an increased ocrelizumab dose did not further slow disability progression but reinforced the efficacy of the approved 600 mg dose.

In this final episode, neurologists discuss the role of advanced imaging, like OCT, in diagnosing and managing MS, emphasizing the need for further research to optimize its clinical application. [WATCH TIME: 2 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 28, 2025.

Tolebrutinib's potential approval as the first brain-penetrant BTK inhibitor for non-relapsing secondary progressive MS and to slow disability accumulation independent of relapse activity could represent a paradigm shift in treating disability driven by smoldering neuroinflammation.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

The interim chief executive officer at the Consortium of Multiple Sclerosis Centers invites healthcare professionals to the Consortium’s annual meeting from May 28–31 in Phoenix, Arizona. [WATCH TIME: 2 minutes]

The associate researcher at the University of California, San Francisco discussed a refined EAE model that could better replicate MS pathology, enabling deeper insights into demyelination, neuronal loss, and remyelination. [WATCH TIME: 6 minutes]

The professor of neurology and neurosurgery at McGill University discussed the evolving understanding of neuroimmune interactions in MS, highlighting how these interactions contribute to disease progression and potential repair mechanisms. [WATCH TIME: 4 minutes]

Daniel Ontaneda, MD, PhD, an associate professor of neurology at the Cleveland Clinic Lerner College of Medicine, gave thoughts and perspectives on some of the emerging, promising advances in multiple sclerosis care expected to come to fruition in 2025.

The assistant professor in the department of neurology at Mount Sinai talked about a recent study that highlighted how socioeconomic status and diet could significantly impact physical and cognitive outcomes in patients with MS. [WATCH TIME: 2 minutes]

The professor of neurology at University of Colorado School of Medicine discussed the evolving landscape of MS treatment, highlighting the role of personalized medicine and biomarker-driven decision-making. [WATCH TIME: 5 minutes]

Treatment strategies varied across cases, incorporating therapies like prednisolone, rituximab, and azathioprine, with overall positive outcomes and symptom improvement.

Here's some of what is coming soon to NeurologyLive® this week.

Catch up on any of the neurology news headlines you may have missed over the course of February 2025, compiled all into one place by the NeurologyLive® team.

The instructor in the department of radiology at Weill Cornell Medicine discussed how structural and functional brain connectomes can potentially improve predictions of MS progression and treatment response. [WATCH TIME: 4 minutes]

A post-hoc analysis of patients from the CHAMPION-NMOSD trial revealed that the majority received their initial meningococcal vaccination within 6-months of their last rituximab dose.

The professor of neurosurgery and physiology at University of Colorado School of Medicine talked about how vagus nerve stimulation may promote remyelination and functional recovery in multiple sclerosis. [WATCH TIME: 4 minutes]